4//SEC Filing
Myles David C. 4
Accession 0001415889-23-015458
CIK 0001750284other
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 7:00 PM ET
Size
13.1 KB
Accession
0001415889-23-015458
Insider Transaction Report
Form 4
Myles David C.
CH. DISCOV. & NON-CLIN DEV OFF
Transactions
- Award
Common Stock
2023-11-20+26,250→ 587,728 total - Sale
Common Stock
2023-11-21$14.87/sh−6,776$100,759→ 580,952 total - Sale
Common Stock
2023-11-21$15.32/sh−200$3,064→ 580,752 total - Sale
Common Stock
2023-11-22$13.89/sh−6,653$92,410→ 574,099 total
Holdings
- 12,831(indirect: See Footnote)
Common Stock
- 154,846(indirect: See Footnote)
Common Stock
Footnotes (8)
- [F1]On November 11, 2022, the Reporting Person was granted certain performance restricted stock units ("PRSUs") for 75,000 shares, which are subject to vesting upon certification by the Compensation Committee of the Company's achieving two different performance milestones. The Compensation Committee certified on November 20, 2023 that 35% of the award vested based upon the certification by the Compensation Committee as to certain performance criteria.
- [F2]Includes 208 shares acquired under the issuer's Employee Stock Purchase Plan on November 15, 2023.
- [F3]The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F4]The weighted average sale price for the transaction reported was $14.87, and the range of prices was between $14.26 and $15.25. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F5]The weighted average sale price for the transaction reported was $15.32, and the range of prices was between $15.28 and $15.35. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F6]The weighted average sale price for the transaction reported was $13.89, and the range of prices was between $13.62 and $14.15. Upon request from the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F7]The shares are held by The Myles Family Revocable Inter Vivos Trust, of which the Reporting Person is trustee.
- [F8]The shares are held by Myles Properties Inc., of which the Reporting Person is President.
Documents
Issuer
Olema Pharmaceuticals, Inc.
CIK 0001750284
Entity typeother
Related Parties
1- filerCIK 0001831216
Filing Metadata
- Form type
- 4
- Filed
- Nov 21, 7:00 PM ET
- Accepted
- Nov 22, 7:00 PM ET
- Size
- 13.1 KB